Discover your next big idea in food packaging & processing this Sept.
Experience a breakthrough in food packaging & processing—explore solutions from 2,300 suppliers spanning all industries at PACK EXPO Las Vegas.
REGISTER TODAY & SAVE

Non-insulin drugs face uphill battle as diabetes care changes

Diabetes care is undergoing a paradigm shift in which insulin is being prescribed earlier, for more conditions, in order to delay the onset of full-blown disease, according to a study released by Scientia Advisors.

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

In light of that trend, as more drugs go generic, companies offering newer, more expensive drugs will face resistance in markets most constrained by economics.
In the words of Harry Glorikian, Scientia’s managing partner, “While there are exciting developments in the non-insulin oral drug categories, the makers of these newer medications would be wise to stay attuned to how to best position their products—especially when marketing in emerging economies, which are extremely sensitive to costs.”

In Glorikian’s words: “ We expect that as more drugs go generic, incretin mimetics (which increase insulin secretion) and insulins will generate an increasing share of the revenues. Therapies with benefits beyond glucose management (such as delaying the onset of diabetes or treating co-morbid conditions) will be used earlier in treatment. For a variety of reasons, despite the growing availability of new types of drugs, various forms of insulin will remain the gold standard. “

The study outlines basic scientific facts about diabetes, diabetes markets in different parts of the world, and mechanisms of action for various diabetes medications. It predicts growth and revenue share for individual drugs and describes “players” and a changing treatment paradigm as affected by traditional, emerging and future drugs and technologies. The study also analyzes how alternative delivery methods (needle-free injection; intranasal, inhaled, dermal, buccal, rectal and new oral methods) will impact insulin usage.

The study, funded by Scientia itself, is based on extensive primary and secondary research and proprietary analytic methods. “Our studies allow us to provide strategic advice that is deeper, more defensible and more expansive than that offered elsewhere,” Glorikian said. “We are pleased to share our insights with clients and prospective clients and to discuss companies’ strategic planning needs.”

The review will be available for download from Scientia’s Web site on Wednesday, Oct. 8, 2009.

Break out of the ordinary: see what’s new in food packaging & processing
<strong>At PACK EXPO Las Vegas you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us this September to experience a breakthrough in food packaging and processing.</strong>
REGISTER NOW AND SAVE!
Break out of the ordinary: see what’s new in food packaging & processing
Researched List: Engineering Services Firms
Looking for engineering services? Our curated list features 100+ companies specializing in civil, process, structural, and electrical engineering. Many also offer construction, design, and architecture services. Download to access company names, markets served, key services, contact information, and more!
Download Now
Researched List: Engineering Services Firms